1. India Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Concord Biotech Ltd.

Concord Biotech Ltd.

1,228.85
INR
-42.25
(-3.32%)
26.06EPS
49.25P/E
134.43BMarket Cap
Nov 18Next Earn
Concord Biotech Ltd.
BSE:CONCORDBIO
(Bombay Stock Exchange)

Recent

price

1,228.85

P/E

ratio

49.25

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
2026
TTM
INR
47.62
57.74
67.72
79.4
95.4
112.78
100.02
105.86
Revenue per Share
16.16
22.45
16.72
22.95
29.45
35.52
24.94
26.09
Basic EPS, GAAP
-0.06
-3.57
4.97
9.65
17.18
12.75
16.42
- -
Free Cash Flow per Basic Share
7.7
0.55
6.74
5.12
6.83
8.75
10.7
- -
Dividend per Share
73.62
95.53
105.45
123.31
145.93
173.27
192.81
- -
Book Value per Share
73.62
94.91
105.11
123.29
145.9
173.17
192.63
- -
Tangible Book Value per Share
105
105
105
105
105
105
105
105
Basic Weighted Avg Shares
4,982
6,041
7,084
8,306
9,981
11,798
10,464
11,084
Sales/Revenue/Turnover
39.07
50.2
33.33
36.69
38.7
39.27
29.13
28.29
Operating Margin (%)
212
275
501
540
536
544
745
748
Depreciation Expense
1,691
2,349
1,749
2,401
3,081
3,716
2,609
2,732
Net Income, GAAP
20.84
24.89
26.35
25.44
25.32
24.85
24.78
25.09
Effective Tax Rate (%)
33.95
38.89
24.69
28.9
30.87
31.5
24.93
24.65
Profit Margin (%)
4,235
5,014
4,775
5,359
7,541
9,512
10,810
- -
Working Capital
385
579
316
64
19
6
14
- -
LT Debt
7,702
9,994
11,032
12,900
15,266
18,127
20,151
- -
Total Equity
- -
23.81
15.04
18.25
20.11
20.7
11.83
- -
Return on Invested Capital (%)
- -
24.64
15.88
19.58
21.69
22.2
13.71
- -
Return on Capital (%)
- -
26.55
16.64
20.06
21.88
22.26
13.63
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
9
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
14
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
105
105
105
Market Capitalization
140,756
106,280
134,432

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
12,501
- -
Cash, Cash Equivalents & STI
- -
4,188
- -
Accounts Receivable, Net
- -
4,602
- -
Inventories
- -
3,264
- -
Total Current Liabilities
- -
1,691
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
9
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
15.11%
11.17%
Free Cash Flow
- -
-12.76%
28.79%
Net Income, GAAP
- -
6.17%
-29.8%
Sales/Revenue/Turnover
- -
12.32%
-11.31%
Total Cash Common Dividend
- -
239.13%
22.29%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2,158
3,102
2,442
4,299
11,798
2026
2,040
2,471
2,778
3,261
10,464
2027
2,575
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
5.7
9.15
7.26
13.42
35.52
2026
4.21
6.03
6.08
8.46
24.94
2027
5.52
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
8.75
2026
- -
- -
- -
- -
10.7
2027
- -
- -
- -
- -
- -
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Concord Biotech Limited, an India-based R&D-driven biopharmaceutical company founded in 1984 and headquartered in Ahmedabad, India, researches, develops, manufactures, markets, and sells fermentation-based active pharmaceutical ingredients, semi-synthetic APIs, and finished dosage formulations across immunosuppressants, anti-bacterial, oncology, anti-fungal, and other therapeutic segments to customers in over 70 countries including the USA, Europe, Japan, and India. The company offers immunosuppressants such as tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, pimecrolimus; oncology products including temsirolimus, everolimus, romidepsin, mitomycin, midostaurin, dactinomycin, staurosporin, mitoguazone, and everolimus premix; anti-bacterials like mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin; anti-fungals comprising anidulafungin, caspofungin, micafungin sodium, amphotericin B, and nystatin; as well as other products such as lovastatin, pravastatin sodium, and enzymes; it also provides nephrology and critical care finished formulations along with contract research and manufacturing services in fermentation and semi-synthesis areas from three manufacturing facilities near Ahmedabad compliant with USFDA, EU-GMP, Japanese PMDA, and other global standards. In recent developments, Concord Biotech approved the acquisition of 100% equity in Celliimune Biotech in November 2025 to enter the cell and gene therapy segment and committed up to 100 million rupees to a solar power project for sustainability; the company secured key regulatory approvals including a USFDA Establishment Inspection Report and EU-GMP certification for its Dholka API facility, Russian GMP inspection completion at Dholka, NAFDAC approval for its Valthera oral solid dosage unit, and EU-GMP for its Limbasi facility, supporting expanded global market penetration amid strategic discussions with innovator firms for API supplies and second-source qualifications.